Obesity and metabolic syndrome predict polyneuropathy over 5 years in recent-onset type 2 diabetes and normal glucose tolerance
Sipola G, Strom A, Wagner R, et al.
Diabetes Metab Res Rev. Pub. online 3 Mar 2026.
Leggi
Breaking news
Additive cardiorenal benefits of finerenone and SGLT2 inhibitor combination therapy in diabetic CKD: a propensity-matched real-world study
Mortada I, Lee A, Sahu A, et al.
Am J Cardiol. Pub. online 27 Feb 2026.
Leggi
A novel chronotype-based mediterranean diet pyramid: an updated representation by the Italian Society of Endocrinology (SIE) and the Italian Society of Dietetics and Clinical Nutrition (ADI)
Barrea L, Verde L, Camajani E, et al.
Curr Nutr Rep. 2026;15(1):10.
Leggi
Impact of early and tight HbA1c control on the risk of long-term complications and cardiovascular death in patients with type 2 diabetes from the Swedish National Diabetes Register
Mount J, Boye K, Lebrec J, Wilkes E, et al.
Diabetes Obes Metab. Pub. online 27 Feb 2026.
Leggi
Sodium-glucose co-transporter 2 inhibitors and obesity-associated cancers in people with type 2 diabetes: a real-world observational study
Ipaye T, Goldney J, Yates T, et al.
Diabetes Obes Metab. Pub. online 26 Feb 2026.
Leggi
Effects of sodium/glucose cotransporter-2 inhibitor use on mortality, amputation, and healing in patients with diabetic foot ulcer
Dumortier C, Aho Glele S, Rouland A, et al.
Diabetes Care. Pub. online 25 Feb 2026.
Leggi
Tubeless automated insulin delivery versus multiple daily injections in children and adults with type 1 diabetes with elevated HbA1c (RADIANT): a multicentre, international, parallel-group, open-label, randomised, controlled trial
Wilmot EG, Beltrand J, Guerci B, et al.
Lancet Diabetes Endocrinol. Pub. online 23 Feb 2026.
Leggi
Comparative efficacy of tirzepatide and glucagon-like peptide-1 receptor agonists on cardiovascular outcomes in patients with type 2 diabetes: a systematic review and network meta-analysis
Shokravi A, Seth J, Mancini GBJ
Cardiovasc Diabetol. Pub. online 27 Feb 2026.
Leggi